Fibrotic complications in ulcerative colitis are associated with early and persistent healthcare burden
Digestive and Liver Disease · 2026-11
DOI: 10.1016/j.dld.2026.10.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2026-11. Verfasst von Ilona Shapiro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Research and Innovation Center, Maccabi Healthcare Services, Israel. Electronic address: shapiro_il@mac.org.il. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck & Co Inc.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Ulcerative colitis (UC) is traditionally considered a mucosal, non-fibrostenosing inflammatory bowel disease, yet emerging evidence suggests that fibrosis is more clinically relevant in UC than previously recognized. Population-based data describing the risk factors and healthcare burden of fibrotic complications in UC are limited. METHODS: We conducted a retrospective population-based cohort study using data from Maccabi Healthcare Services, a nationwide insurer-provider. Non-malignant strictures, stenosis, or obstruction post-UC diagnosis were used as a proxy for fibrotic complications. Risk factors were assessed using Cox regression. Patients with fibrotic complications were then matched to controls to compare healthcare resource utilization (HCRU) and treatment patterns. RESULTS: Among 6,944 patients with UC, 100 (1.4%) developed fibrotic complications. Older age at diagnosis (HR [95%CI]=1.81[1.05-3.13] for ages 41-65 and 2.75[1.30-5.80] for >65 vs. 18-40), comorbidities (1.73[1.04-2.88]), and advanced therapy exposure (4.38[2.47-7.74]) were independently associated with increased risk of fibrotic complications, whereas proctitis at presentation was protective (0.49[0.31-0.78]). Patients with fibrotic complications had higher HCRU, medication use, and costs throughout the disease course, evident even before fibrotic complication diagnosis, with a further increase in HCRU post-diagnosis. CONCLUSIONS: Fibrotic complications in UC are associated with substantial clinical and healthcare burden, underscoring the need for improved risk stratification, earlier recognition, and further investigation of targeted antifibrotic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Maccabi Research and Innovation Center, Maccabi Healthcare Services, Israel. Electronic address: shapiro_il@mac.org.il.
- Merck & Co., Inc., Rahway, NJ, USA.
- Maccabi Research and Innovation Center, Maccabi Healthcare Services, Israel.
Förderung
- Merck & Co Inc
Zitieren
APA
Shapiro, I., Igho-Osagie, E., Sharman Moser, S., Lawlor, G., Hoshen, M., Liu, G., Gazit, S., Rieder, F., & Ben-Tov, A. (2026). Fibrotic complications in ulcerative colitis are associated with early and persistent healthcare burden. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.10.031
Vancouver
Shapiro I, Igho-Osagie E, Sharman Moser S, Lawlor G, Hoshen M, Liu G, et al. Fibrotic complications in ulcerative colitis are associated with early and persistent healthcare burden. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.10.031
BibTeX
@article{Shapiro2026,
author = {Shapiro, Ilona and Igho-Osagie, Ebuwa and Sharman Moser, Sarah and Lawlor, Garrett and Hoshen, Moshe and Liu, Gui and Gazit, Sivan and Rieder, Florian and Ben-Tov, Amir},
title = {Fibrotic complications in ulcerative colitis are associated with early and persistent healthcare burden},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2026.10.031}
}
EUVIMED